Packaging protein drugs as bacterial inclusion bodies for therapeutic applications
Villaverde Corrales, Antonio (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Garcia-Fruitos, Elena (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Rinas, Ursula (Helmholtz-Zentrum für Infektionsforschung)
Seras-Franzoso, Joaquin (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Kosoy, Ana (Janus Development SL)
Corchero Nieto, José Luis (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Vázquez Gómez, Esther (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")

Data:	2012
Resum:	A growing number of insights on the biology of bacterial inclusion bodies (IBs) have revealed intriguing utilities of these protein particles. Since they combine mechanical stability and protein functionality, IBs have been already exploited in biocatalysis and explored for bottom-up topographical modification in tissue engineering. Being fully biocompatible and with tuneable bio-physical properties, IBs are currently emerging as agents for protein delivery into mammalian cells in protein-replacement cell therapies. So far, IBs formed by chaperones (heat shock protein 70, Hsp70), enzymes (catalase and dihydrofolate reductase), grow factors (leukemia inhibitory factor, LIF) and structural proteins (the cytoskeleton keratin 14) have been shown to rescue exposed cells from a spectrum of stresses and restore cell functions in absence of cytotoxicity. The natural penetrability of IBs into mammalian cells (reaching both cytoplasm and nucleus) empowers them as an unexpected platform for the controlled delivery of essentially any therapeutic polypeptide. Production of protein drugs by biopharma has been traditionally challenged by IB formation. However, a time might have arrived in which recombinant bacteria are to be engineered for the controlled packaging of therapeutic proteins as nanoparticulate materials (nanopills), for their extra- or intra-cellular release in medicine and cosmetics.
Ajuts:	Ministerio de Ciencia e Innovación BFU2010-17450 Agència de Gestió d'Ajuts Universitaris i de Recerca 2009/SGR-108
Nota:	Altres ajuts: A. Villaverde has been granted with an ICREA ACADEMIA award (from ICREA, Catalonia, Spain) and EGF is supported by the Programa Personal de Técnico de Apoyo (Modalidad Infraestructuras científco-tecnológicas, MICINN). JSF is a PIF fellowship holder from UAB, Spain.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Microbial cell factories, Vol. 11 (June 2012) , art. 76, ISSN 1475-2859

DOI: 10.1186/1475-2859-11-76
PMID: 22686540

5 p, 470.7 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Biotecnologia i de Biomedicina (IBB)
Articles > Articles de recerca
Articles > Articles publicats